✦ LIBER ✦

Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin

✍ Scribed by Ei Tae Kim; Lee Hoo Kim; Jung Il Lee; Hee Seung Chin

Publisher: Springer
Year: 2009
Tongue: English
Weight: 181 KB
Volume: 53
Category: Article
ISSN: 0021-5155
DOI: 10.1007/s10384-009-0738-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of re-treatment with pegylated

Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan

✍ Tsugiko Oze; Naoki Hiramatsu; Takayuki Yakushijin; Kiyoshi Mochizuki; Masahide O 📂 Article 📅 2011 🏛 Springer Japan 🌐 English ⚖ 297 KB

Combination therapy with interferon-α an

Combination therapy with interferon-α and ribavirin as immunomodulators in patients with chronic hepatitis C

✍ Norio Horiike; Morikazu Onji 📂 Article 📅 2003 🏛 Springer Japan 🌐 English ⚖ 132 KB

Merimepodib, pegylated interferon, and r

Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders

✍ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a

Retreatment of patients with chronic hep

Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine

✍ Rudolf E Stauber; Harald Hofer; Franz Hackl; Kurt Schüze; Christian Datz; Karin 📂 Article 📅 2004 🏛 Springer Vienna 🌐 English ⚖ 738 KB

Effectiveness of hepatitis C treatment w

Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients

✍ Paul Feuerstadt; Ari L. Bunim; Heriberto Garcia; Jordan J. Karlitz; Hatef Massou 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB 👁 2 views

Randomized controlled trials of hepatitis C virus (HCV) therapy with pegylated interferon and ribavirin have demonstrated sustained viral response rates (SVRs) of 54%-63% (efficacy). Treatment results in clinical practice (effectiveness) may not be equivalent. The goal of this study was to assess th

Effectiveness of hepatitis C treatment w

Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients

✍ Ezequiel Ridruejo; Raúl Adrover; Daniel Cocozzella; María Virgina Reggiardo; Nor 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 495 KB 👁 2 views

This study was partially supported by grants UBACYT M055 (Universidad de Buenos Aires) and PICT 06-124 (Agencia Nacional de Promocio´n Cien-tı´fica y Tecnolo´gica).